Pharma's Market
SPECIAL REPORT
MOST SHARED
- Marc Faber: 100% Chance of Global Recession
- Zero China Growth Is ‘Probable’: Gordon Chang
- Time for Flash Sales to Adapt or Die
- Citigroup Lost $20 Million on Facebook IPO Trades
- 5 Spots Where the Dollar Buys a Great Vacation
- Facebook: The Song — Yes, We're Serious
- How to Trade on the Jobs Report
- China Growth Risks Signal Need for Fiscal Action
- What College Tuition Will Look Like in 18 Years
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- Citigroup Lost $20 Million on Facebook IPO Trades
- Sticker Shock: What College Is Likely to Cost in 18 Years
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- Icahn Raises Stake in Chesapeake, Wants Board Seats
- Marc Faber: Chance of Global Recession Is Now 100%
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- What Happened to Stocks? Most Unloved in 50 Years
- Cool Jobs: From Gold Stacker to Bed Tester
- Many Greeks Moved Their Money Abroad Long Ago
RSS FEED
Drug Money Still A "Healthy Flow" To Democrats
Text Size 
Reporter
 |
CNBC.com |
But, when the CRP, on its web site, www.opensecrets.org, breaks it down to just the drug manufacturers (i.e. Amgen [AMGN
Loading...
()
] , Pfizer [PFE
Loading...
()
] , GlaxoSmithKline [GSK
Loading...
()
] , etc.), Obama beats Clinton by 3-grand. Sen. John McCain remains in 15th place on the list of presidential/congressional candidate recipients of money from pharma/health products. But since the last report, he's moved up two notches to 11th position on the recipient list from drugmakers. Gov. Mike Huckabee doesn't appear in the top-20 in either category.
You can check out the pharma/health products recipient list here and the drug manufacturers' list here.
According to the CRP, the pharma/health products sector is now splitting its donations evenly between Democrats and Republicans. In the last presidential election cycle it favored the GOP by a two-to-one margin. While the drugmakers, so far, have given 47 percent of their campaign cash to Dems and 53 percent to Republicans. In 2004, it was 30-70, respectively.
Biotech behemoth Amgen is still the biggest giver (nearly three-quarters of a million dollars), followed by Pfizer, Glaxo, Johnson and Johnson [JNJ
Loading...
()
] and Roche (which owns a majority stake in another biotech giant, Genentech [DNA
Loading...
()
] ). Most, but not all, of the individual drug companies are giving more of their money to Republicans (Pfizer, whose CEO has twice given the maximum personal contribution to Clinton, is one of the exceptions).
And, interestingly, generic drugmaker Mylan Labs [MYL
Loading...
()
] , favors Democrats (67 percent) over Republicans (33 percent). Perhaps the conventional political wisdom there is that the Dems might work harder to make it easier to get cheaper generic drugs to market. And sleeping pill manufacturer Sepracor [SEPR
Loading...
()
] (it makes Lunesta--the one with the opaque butterfly in the commercial) has thrown 83 percent of its cash at Democrats.
Analysts say the industry is simply trying to make sure it has a place at the table if/when healthcare reform is discussed. Others say it supports their thesis that the Democrats' bark might be worse than their bite--that yes, there's a lot of populist campaign rhetoric about "taking on the drug companies," but that the financial support may be a better "tell" of their true position when push comes to shove. Our chief political correspondent, John Harwood, says the flow of pharma funds to the presidential candidates tells you more about the way the election is tilting than any voter poll.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
